Back to discover
Disease

Phenylketonurias

Late-stage therapeutic developmentEmerging researchRising momentum
3
Publications
6
Clinical trials
2025
Latest publication
Current focus
Therapeutic developmentGenetics & risk factorsMetabolic & lifestyle factors
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

Approval: Sephience (EMA)

Regulatory2025-06-19EMA

Approval: Sapropterin Dipharma (EMA)

Regulatory2022-02-16EMA

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Clinical trials

4 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Research activity

3 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
20182025
Major themes7
  • Escherichia coli1
  • Gastrointestinal Microbiome1
  • Genetic Therapy1
  • Metabolic Engineering1
  • Phenylalanine Hydroxylase1
  • Phenylketonurias1
  • Synthetic Biology1
Leading journals3
  • American journal of human genetics1
  • Archives of microbiology1
  • Nature biotechnology1
Leading researchers8
  • Ahrens-Nicklas RC1
  • Anderson CL1
  • Bergeron CG1
  • Brooks DL1
  • Castillo MJ1
  • Falb D1
  • Fisher AB1
  • Guilmain SE1
Affiliations (unnormalised)5
  • Cardiovascular Institute1
  • College of Veterinary Medicine1
  • Medical School1
  • Perelman School of Medicine at the University of Pennsylvania1
  • Swami Vivekananda Institute of Modern Sciences1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

A group of autosomal recessive disorders marked by a deficiency of the hepatic enzyme PHENYLALANINE HYDROXYLASE or less frequently by reduced activity of DIHYDROPTERIDINE REDUCTASE (i.e., atypical phenylketonuria). Classical phenylketonuria is caused by a severe deficiency of phenylalanine hydroxylase and presents in infancy with developmental delay; SEIZURES; skin HYPOPIGMENTATION; ECZEMA; and demyelination in the central nervous system. (From Adams et al., Principles of Neurology, 6th ed, p952).

References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.